JP2021518111A5 - - Google Patents
Info
- Publication number
- JP2021518111A5 JP2021518111A5 JP2020549002A JP2020549002A JP2021518111A5 JP 2021518111 A5 JP2021518111 A5 JP 2021518111A5 JP 2020549002 A JP2020549002 A JP 2020549002A JP 2020549002 A JP2020549002 A JP 2020549002A JP 2021518111 A5 JP2021518111 A5 JP 2021518111A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- nucleic acid
- cell
- amino acid
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023114641A JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643139P | 2018-03-14 | 2018-03-14 | |
| US62/643,139 | 2018-03-14 | ||
| PCT/US2019/021833 WO2019178085A1 (en) | 2018-03-14 | 2019-03-12 | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114641A Division JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518111A JP2021518111A (ja) | 2021-08-02 |
| JP2021518111A5 true JP2021518111A5 (enExample) | 2022-03-18 |
| JP7314161B2 JP7314161B2 (ja) | 2023-07-25 |
Family
ID=67907266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549002A Active JP7314161B2 (ja) | 2018-03-14 | 2019-03-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
| JP2023114641A Active JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114641A Active JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12606603B2 (enExample) |
| EP (2) | EP4491718A3 (enExample) |
| JP (2) | JP7314161B2 (enExample) |
| KR (2) | KR20260021083A (enExample) |
| CN (1) | CN112088165A (enExample) |
| AU (2) | AU2019234580B2 (enExample) |
| BR (1) | BR112020018534A2 (enExample) |
| CA (1) | CA3093791A1 (enExample) |
| EA (1) | EA202091984A1 (enExample) |
| IL (1) | IL277268A (enExample) |
| MX (2) | MX2020009464A (enExample) |
| SG (1) | SG11202008926RA (enExample) |
| WO (1) | WO2019178085A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020018670A2 (pt) | 2018-03-14 | 2021-01-05 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Receptor de antígeno quimérico de receptor alfa 2 da il-13 (il13ra2) para imunoterapia com células t específicas para tumor |
| WO2024041650A1 (en) * | 2022-08-25 | 2024-02-29 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090257994A1 (en) * | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| SG186017A1 (en) | 2007-11-30 | 2012-12-28 | Kalobios Pharmaceuticals Inc | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
| US8822647B2 (en) | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
| ES2717629T3 (es) * | 2009-11-03 | 2019-06-24 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas |
| EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| PL3824905T3 (pl) | 2012-08-20 | 2025-05-05 | Fred Hutchinson Cancer Center | Sposób i kompozycje do immunoterapii komórkowej |
| HK1214161A1 (zh) | 2012-11-07 | 2016-07-22 | 辉瑞公司 | 抗IL-13受体α2抗体和抗体-药物缀合物 |
| CA2893359C (en) | 2012-12-05 | 2021-12-28 | Strategia Therapeutics, Inc. | Protein expression enhancing polypeptides |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| EP3974520A1 (en) * | 2013-05-14 | 2022-03-30 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| EP3587446A1 (en) * | 2014-09-19 | 2020-01-01 | City of Hope | Costimulatory chimeric antigen receptor t cells targeting il13 r alpha 2 |
| JP7264592B2 (ja) | 2015-01-26 | 2023-04-25 | ザ ユニバーシティー オブ シカゴ | ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用 |
| AU2016297605A1 (en) | 2015-07-21 | 2018-02-15 | City Of Hope | T cells for expression of chimeric antigen receptors and other receptors |
| CN116334205A (zh) * | 2015-09-03 | 2023-06-27 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
| BR112018015836A2 (en) * | 2016-02-05 | 2018-12-26 | City Of Hope | engineered t-cell administration for central nervous system cancer treatment |
| WO2017172981A2 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| KR20190015520A (ko) | 2016-06-07 | 2019-02-13 | 마크로제닉스, 인크. | 조합 치료법 |
| CA3031955A1 (en) | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| JP2019530440A (ja) * | 2016-09-02 | 2019-10-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物 |
| US12083148B2 (en) | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| BR112020018670A2 (pt) | 2018-03-14 | 2021-01-05 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Receptor de antígeno quimérico de receptor alfa 2 da il-13 (il13ra2) para imunoterapia com células t específicas para tumor |
-
2019
- 2019-03-12 EP EP24214241.2A patent/EP4491718A3/en active Pending
- 2019-03-12 WO PCT/US2019/021833 patent/WO2019178085A1/en not_active Ceased
- 2019-03-12 CN CN201980030021.9A patent/CN112088165A/zh active Pending
- 2019-03-12 KR KR1020267001996A patent/KR20260021083A/ko active Pending
- 2019-03-12 SG SG11202008926RA patent/SG11202008926RA/en unknown
- 2019-03-12 MX MX2020009464A patent/MX2020009464A/es unknown
- 2019-03-12 JP JP2020549002A patent/JP7314161B2/ja active Active
- 2019-03-12 BR BR112020018534-5A patent/BR112020018534A2/pt not_active Application Discontinuation
- 2019-03-12 US US16/979,475 patent/US12606603B2/en active Active
- 2019-03-12 EP EP19767433.6A patent/EP3765487A4/en not_active Withdrawn
- 2019-03-12 AU AU2019234580A patent/AU2019234580B2/en active Active
- 2019-03-12 CA CA3093791A patent/CA3093791A1/en active Pending
- 2019-03-12 KR KR1020207028968A patent/KR102917671B1/ko active Active
- 2019-03-12 EA EA202091984A patent/EA202091984A1/ru unknown
-
2020
- 2020-09-10 MX MX2025010440A patent/MX2025010440A/es unknown
- 2020-09-10 IL IL277268A patent/IL277268A/en unknown
-
2023
- 2023-07-12 JP JP2023114641A patent/JP7696958B2/ja active Active
-
2024
- 2024-04-24 AU AU2024202681A patent/AU2024202681A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518108A5 (enExample) | ||
| US20250043013A1 (en) | Nucleic acids encoding il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy | |
| JP6543626B2 (ja) | 多部分シグナル伝達タンパク質およびその使用 | |
| EP3445847B1 (en) | Immunomodulatory il2r fusion proteins and uses thereof | |
| US20170292118A1 (en) | Method for modulating car-induced immune cells activity | |
| JP7696958B2 (ja) | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 | |
| EP4382119A1 (en) | A kit for use in the treatment of hematological cancer | |
| JP2025540251A (ja) | 血液癌の治療において使用するためのキット | |
| WO2023102109A1 (en) | Ex vivo cytokine priming strategies for preparing activated cd26-high immune cells and uses in cancer therapies | |
| JP2023529443A (ja) | 抗ｃｄ１７１キメラ抗原受容体 | |
| KR20260032682A (ko) | 두경부암 치료를 위한 egfr을 표적으로 하는 키메라항원 수용체 및 이를 발현하는 t 세포 치료제 |